Patent Application

App. No. 16/958,240

Abstract

Claims (31)

1 . A method for typing an allograft recipient for the presence or absence of an antibody mediated rejection (ABMR), comprising the steps of

measuring in a sample comprising proteins from an allograft recipient a protein level for at least two genes selected from the group consisting of TF, SERPINA1, APOA4, AFM, AZGP1, ORM1, ORM2, C3, A1BG, SERPINC1, LRG1, IGHA1, IGHG4, TFAP2C, HPX, A2M, CARD6, SERPINA7, CCDC73, CYSTM1 and APOA1;

comparing said measured protein level to a reference protein level for said at least two genes; and

typing said allograft recipient for the presence or absence of an ABMR on the basis of the comparison of the measured protein level and the reference protein level.

2 . The method according to claim 1 , wherein the method is for typing a sample of said allograft recipient for the presence or absence of an ABMR.

3 . The method according to claim 1 , wherein the allograft recipient is a renal allograft recipient.

4 . The method according to claim 1 , wherein the sample is a body fluid sample.

5 . The method according to claim 1 , wherein a protein level is measured for at least 6 genes selected from the group consisting of TF, SERPINA1, APOA4, AFM, AZGP1, ORM1, ORM2, C3, A1BG, SERPINC1, LRG1, IGHA1, IGHG4, TFAP2C, HPX, A2M, CARD6, SERPINA7, CCDC73, CYSTM1 and APOA1.

6 . The method according to claim 1 , wherein a protein level is measured for at least two genes selected from the group consisting of A1BG, AFM, APOA1, APOA4, IGHA1, IGHG4, LRG1, SERPINA1, SERPINC1 and TF.

7 . The method according to claim 6 , wherein a protein level is measured for at least 6 genes selected from the group consisting of A1BG, AFM, APOA1, APOA4, IGHA1, IGHG4, LRG1, SERPINA1, SERPINC1 and TF.

8 . The method according to claim 1 , wherein said allograft recipient, or sample thereof, is typed as having an ABMR when said protein levels are increased as compared to a reference protein level for said at least two genes in a reference sample of an allograft recipient not having an ABMR.

9 . The method according to claim 1 , further comprising the steps of:

digesting proteins in said sample with trypsin so as to provide a mixture of peptides;

subjecting said mixture of peptides to a step of liquid chromatography so as to provide an eluate comprising peptides; and

performing a step of mass spectrometry on said eluate to measure a peptide level for at least two peptides, said peptide level for said at least two peptides representing the protein level for said at least two genes.

10 . The method according to claim 9 , wherein said at least two peptides are selected from SEQ ID NOs: 1-22.

11 . The method according to claim 1 , wherein measurement of said protein level is performed by an enzyme-linked immunosorbent assay (ELISA).

12 . A method for assigning an allograft recipient to an ABMR group or a non-ABMR group comprising the steps of:

measuring in a sample comprising proteins from an allograft recipient suffering, or at risk of suffering, from transplant rejection a protein level for at least two genes selected from the group consisting of TF, SERPINA1, APOA4, AFM, AZGP1, ORM1, ORM2, C3, A1BG, SERPINC1, LRG1, IGHA1, IGHG4, TFAP2C, HPX, A2M, CARD6, SERPINA7, CCDC73, CYSTM1 and APOA1;

comparing said measured protein level to a reference protein level for said at least two genes; and

assigning said allograft recipient to said ABMR group or to said non-ABMR group on the basis of the comparison of the measured protein level and the reference protein level.

13 . The method of claim 1 wherein the sample is a urine sample and at least two proteins from the at least two genes serve as a marker for the presence or absence of an ABMR in an renal allograft recipient.

14 . A standard-of-care therapeutic agent for use in the treatment of an allograft recipient suffering from transplant rejection associated with an ABMR, wherein said recipient, or a sample thereof, is typed as having an ABMR according to the method of claim 1 .

15 . The standard-of-care therapeutic agent for use according to claim 14 , wherein said agent is selected from the group consisting of corticosteroids, rituximab, intravenous immunoglobulin (IVIG) products, bortezomib, eculizumab and combinations thereof; and wherein said agent is for administration according to a therapeutically effective dosing regimen.

16 . A method for treating an allograft recipient suffering from transplant rejection associated with an ABMR, comprising the steps of:

administering a therapeutically effective amount of a standard-of-care therapeutic agent to an allograft recipient suffering from transplant rejection associated with an ABMR, wherein said recipient, or a sample thereof, is typed as having an ABMR according to the method of claim 1 .

17 . A standard-of-care therapeutic agent for use in the treatment of an allograft recipient suffering from transplant rejection associated with an ABMR, wherein said recipient, or a sample thereof, is assigned to the ABMR group according to a method of claim 12 .

18 . The standard-of-care therapeutic agent for use according to claim 17 , wherein said agent is selected from the group consisting of corticosteroids, rituximab, intravenous immunoglobulin (IVIG) products, bortezomib, eculizumab and combinations thereof; and wherein said agent is for administration according to a therapeutically effective dosing regimen.

19 . A method for treating an allograft recipient suffering from transplant rejection associated with an ABMR, comprising the steps of:

administering a therapeutically effective amount of a standard-of-care therapeutic agent to an allograft recipient suffering from transplant rejection associated with an ABMR, wherein said recipient, or a sample thereof, is assigned to the ABMR group according to a method of claim 12 .

20 . The method of claim 19 wherein the standard-of-care therapeutic agent is selected from the group consisting of corticosteroids, rituximab, intravenous immunoglobulin (IVIG) products, bortezomib, eculizumab and combinations thereof; and wherein said agent is for administration according to a therapeutically effective dosing regimen.

Assignments (8)